Skip to main content

Recent Scientific Presentations


  • Introduction to Fragment Based Drug Discovery
    Christopher Smith
    BIT 5th UCLA, January 20, 2015 Los Angeles, California


  • Fragment Based Drug Discovery. Sweating the Small Stuff is Worth it
    Gavin Hirst
    BIT 5th International Conference on Medicinal Chemistry, November 18-20, 2014 Shanghai, China
  • High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875
    Gyorgy Snell
    PSDI 2014 Protein Structure Determination in Industry, November 2-4, 2014 Lisbon, Portugal
  • Fragment Based Lead Generation: Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase
    Christopher Smith
    Fragment Based Lead Discovery Conference 2014, September 21-24, 2014 Basel, Switzerland
  • Structural Insights Into Allosteric Agonist Bound human GPR40 (hGPR40)
    Ankita Srivastava
    September 10, 2014
  • Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation
    Steven Woodhead
    XXIII EFMC-ISMC Symposium, September 9, 2014 Lisbon, Portugal
  • The Impact of Compound Properties on Attrition Risk
    Matthew Marx
    Gordon Research Seminar, August 2, 2014
  • Fragment Based Lead Generation: A Rich Source for Designing Selective Bruton's Tyrosine Kinase Inhibitors
    Mark Sabat
    Zing Conference, July 19-22, 2014 Punta Cana, Dominican Republic
  • How Safe is your Drug? - The Toxicologist's Race from Discovery to IND
    Raymond Liu
    CACO-PBSS (Pharmaceutical and BioScience Society), June 27, 2014 La Jolla, California
  • Preformulation Approaches to Enhance Solubility/Bioavailability of Poorly Soluble Drug Candidates
    Rongliang Chen
    The 2nd Drug Formulation & Bioavailability West Conference, June 2-3, 2014 San Diego, California
  • Process Research and Kilogram Synthesis of TAK-733, an Investigational, Potent MEK inhibitor
    Yuxin Zhao
    Cambridge Healthtech Institute's 7th International Efficient Process Chemistry Meeting, May 22-23, 2014 Boston, Massachusetts
  • Use of Fragment-based drug design in the discovery of two series of potent methionine aminopeptidase-2 inhibitors
    Christopher McBride
    CHI Drug Discovery Chemistry Meeting, April 22-13, 2014 San Diego, California
  • UCSD lectures on biologics
    Aaron Chamberlain
    UCSD, April 2, 2014 San Diego, California
  • Discovery of Nesina - The Whole Story
    Betty Lam
    March 27, 2014
  • The Challenge of ADC Target Identification & Validation
    Patrick Vincent
    World ADC Frankfurt, February 20, 2014 Frankfurt, Germany
  • The Role of Analytics in the Design and Control of Antibody Drug Conjugates
    Samadhi Vitharana
    Cambridge Health Institute's 13th Annual PEP Talk, January 13-17 Palm Springs, California
  • Discovery of a small molecule inhibitor of Burton's Tyrosine Kinase (BTK) for autoimmune diseases
    Loui Madakamutil


  • Accelerating Drug-target simulations in Lipid Bilayers with GPUs
    Andrew Jennings
    GPU Conference, November 5-6, 2013 San Diego, California
  • Machine Learning Applications with Jchem
    Steve Wilkens
    ChemAxon, September 24, 2013
  • Extracting Chemical Knowledge From Patents
    Steve Wilkens
    ChemAxon, September 24, 2013
  • An Introduction to Fragment Based Drug Discover
    Christopher Smith
    Academics to Industry, July 23, 2013
  • A review of strategies to interrogate p38? and JNK1 using affinity-based methods and FBDD
    Steve Swann
    July 17, 2013
  • SFC method development for scale up purification: UPC2/MS vs. parallel SFC/MS
    Lu Zeng
    June 26, 2013
  • From high throughput to high difficulty: the evolution of protein crystallography for drug discovery
    Gyorgy Snell
    APS User Meeting, May 9, 2013
  • Process Chemistry - Roles and Objectives in Support of Drug Development Programs
    Wolfgang Notz
    March 11, 2013
  • High-resolution Structure Of GPR40 Receptor Bound To Partial Agonist TAK-875 (Fasiglifam)
    Ankita Srivastava
    GPCR Workshop, 2013


  • Discovery of NESINA (alogliptin), a Highly Selective Dipeptidyl Peptidase-IV inhibitor for the Treatment of Type 2 Diabetes
    Robert Wynands
    12th International Kyoto Conference on New Aspects of Organic Chemistry, November, 12, 2012 Kyoto, Japan
  • tructure-Based Drug Design - Increasing the Likelihood to Create New Medicines
    Kathleen Aertgeerts
    10th Annual Congress of International Drug Discovery Science and Technology, November 8-10, 2012 Hanjing, China
  • Impact of Machine Learning in Predictive ADME and Kinase Selectivity
    Steve Wilkens
    UKQSAR Conference, November 8, 2012 Cambridge University
  • Recent Developments in the Carcinogenicity Assessment of the Biotechnology-derived Pharmaceuticals
    Ronald Steigerwalt
    American College of Toxicology, November 6, 2012
  • Evaluation of New UPC2/MS System
    Lu Zeng
    September 27, 2012
  • Just Another Chemical Query Tool or Not
    Matthew Pustelnik
    ChemAxon User Group Meeting, September 25-26, 2012 Boston, Massachusetts
  • Compound Progression Workflow
    Matthew Pustelnik
    ChemAxon User Group Meeting, September 25-26, 2012 Boston, Massachusetts
  • Structure based drug design and optimization of potent inhibitors of Polo-like Kinase 1 (PLK1)
    Christopher McBride
    Technical Achievements in Organic Chemistry Award Symposium, August 22, 2012 Philadelphia, Pennsylvania
  • An Analytical Toolbox for Rapid Formulation Development of a Monoclonal Antibody
    Kamal Kannan
    CACO Pharmaceutical and Bioscience Society, August 10, 2012
  • Advanced SFC/MS technologies to support drug discovery and development
    Lu Zeng
    June 29, 2012
  • The Application of Calorimetry in Fragment Drug Discovery
    Yiqin Wu
    Biacore/ITC User Conference, 2012 San Diego, California


  • Discovery of TAK-960: an Orally Available Small Molecule Inhibitor of Polo-Like Kinase 1 (Plk1)
    Zhe Nie
    242nd ACS National Meeting, August 28, 2011 Denver, CO
  • Developing an Analytical Methods Platform to Support ADCs - Finding the Optimal Antibody Drug Combination
    Mike Buckley
    World ADC Summit, February 21, 2011 Frankfurt, Germany
  • The Influence of Antigen, Antibody and ADC Properties in In Vitro and In Vivo Cytotoxicity
    Gregory Landes
    Antibody Drug Products Meeting at CHI PepTalk, January 10, 2011 San Diego, CA


  • Development of New Chiral Chromatographic Methods for the Analysis and Purification of Pharmaceutical Samples
    Lu Zeng
    Chirality 2010, July 11 -15, 2010 Sapporo, Japan
  • Discovery of NesinaTM, a Potent DPP-4 Inhibitor for the Treatment of Diabetes Mellitus Type 2, using Structural Enzymology Approaches
    Kathleen Aertgeerts
    EMBO Conference Series: Catalytic Mechanisms by Biological Systems: at the interface between chemistry and biology, May 7, 2010 Hamburg, Germany
  • Fragment-based discovery of TAK-901, a novel multi-targeted Aurora B kinase inhibitor
    Ron de Jong
    101st AACR Annual Meeting, April 17-21, 2010 Washington, DC
  • Antibody Target Discovery
    Mary Haak-Frendscho
    4 Annual Proteins Congress, April 4th, 2010 London, England